FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 348 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Non-pharmacological interventions – are they important to patients with cancer? Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer MOST POPULAR Different Microbiota–Host Relationships Relevant to Distinct Immune Checkpoint Blockade Regimens March 21, 2024 Noninferiority of OS with 3 Months Compared to 6 Months of... January 20, 2026 Telehealth-Based Cancer Care Surged during COVID. Will It Continue? March 9, 2022 Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with... April 9, 2026 Load more HOT NEWS Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than... Can Being Exposed to Wildfire Smoke Affect Your Cancer Risk?
